Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
New to investing? Check out these zero fee investment apps designed specifically for new investors to start building wealth.
28,005 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Take a practical tour of arcutis (arqt) 2026 earnings, from revenue mix and margins to pipeline progress and risk fac...
A sudden drop in Navitas stock sent ripples through growth-focused portfolios. This guide explains the key drivers, w...
Insider moves often spark questions when a stock rallies. This article examines Nayax's CMO sale during a solid run, ...
Amazon’s biggest growth lever may not be its storefront. This article explains how AWS and AI spending could fuel a ...
Greg Abel leads Berkshire Hathaway as the company holds a record cash pile. This in-depth guide explains what that me...
Investors are weighing a bold claim: prediction: will lose value for XRP. This article breaks down what could drive X...
Taiwan Semiconductor is in the spotlight as it signals higher capital spending. This article breaks down whether tsmc...
Nvidia just beat earnings expectations, yet the stock fell in the following days. This article breaks down what the p...
A fast-growing tech name in the AI space has dazzled investors, but a recent funding move underscored a crucial risk....
A dramatic May rally sent applied digital stock skyrocketed as AI optimism surged. This piece breaks down the drivers...
Rocket Lab isn’t profitable yet, but the space company shows four clear catalysts for investors. Here are practical r...